Feb 24, 2025NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant PatientsRead moreView PDF
Feb 04, 2025NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical OfficerRead moreView PDF
